Валдис плюс 400 мг/90 мг таблетки, покрытые пленочной оболочкой

국가: 키르기스스탄

언어: 러시아어

출처: Правительства Кыргызской Республики (Департамент лекарственного обеспечения и медицинской техники)

유효 성분:

Софосбувир+Ледипасвир

제공처:

SHROOQ PHARMACEUTICALS (PVT) LTD

ATC 코드:

J05AX65

INN (International Name):

Sofosbuvir+Ledipasvir

복용량:

400 мг/90 мг

약제 형태:

таблетки, покрытые пленочной оболочкой

패키지 단위:

№28

처방전 유형:

по рецепту

Manufactured by:

SHROOQ PHARMACEUTICALS (PVT) LTD (Пакистан)

치료 영역:

Прочие противовирусные препараты

제품 요약:

ПЖВЛС: нет

승인 날짜:

2016-10-26

제품 특성 요약

YTBEPXTNAIO
Hbrfi
AupeKTop
fo
o0ecIIe
II
TEXHIIKII
M
r4HCTpyK
Wfl
rIO MEAI,IUI4HCKOMy
IIPI{MEHEHI,ITO
JIEKAPCTBEHHO|
O
CPENCTBA
BAJINI{C
fIJIIOC
Topronoe
Ha3BaHlre
Ba,rArac
llnroc/
Valdis Plus
MexaynapoAHoe
HerrareHToBaHHoe
Ha3BaHIre
Ile4unacnup
+CoSoc6ynup
JlercapcrneHHafl
Sopnra
Ta6,rerxu,
noKplrrble
ueuoquofi
o6oloqxofi
.
Cocras:
B rcaxlofi'ra6lerxe,
norcprrroft
nlenoquofi o6oroqxofi
coAepxarcl4eficrnyroque
BeilIecrBa:
neAr4nacBup
-
90
ltr,
co$oc6yBl{p
-
400
vr
BcnouozamerbHue
seu4ecm6a.'Mr,rrcpoxpucra,'IJurqecKas
Ilennrcno3a
(aBI4IIen
pH
102),:raxro:a,
HarpLIf,
KpaxMaJr
fruKorqr,
creapar
MafHr'I-fl
.
ITneHoquan
o6ono.trca:
Merorlr{Jr
E-5
(rzgpoKcrrlpolunMerl4nueJlJlrolosa), Ir3onponllnoertfi
crrr4pr.
flSf:6000,
creapar
MafHLIt,
AzoKcLIA
TLrraHa
(E-171),
TaJrbK.
O n u c a u u e :
Ee,rrre,
noKpbrrbre
n,teuo.+rofi
o6o,roqroli,
upoAonfoearofi
$opuu
ra6:rerxra
c
rpaBl4poBanuofi
HaArrrrcbro
Shrooq
sa oAHoti
cropoHe
14
rnaAKlie
c
4pyrofi
cropoHbt.
@apuarcoreparreBTlrqecKaq
rpyflrra:
flpo'rueoeupycHbre
npetraparbr
Anq
cr4creMHoro
nplIMeHeHI{x.
llporunoBI,IpycHbIe
npeilaparbl
npsMofo
Aeficrauq.
Koa
ATX
.105AX65
Qapn'raroror-HrrecKoe
4eiicrnue
Mexauusu deilcmaun
JleAunaceup
rBn.f,ercs uuru6uropoM
Br{pyca renarr4ra
C, eos4eficrByroull4M
na NS5A-6e:ror<
Brpyca rerrarura C,
rcoropufi
y.racrnyer
B
pennnKauun
PHK r4
Bllcrynaer
BaxHbIM 3neMeHToM
Soplluponarinr
o6,racru cKolreHr4q
Br4pL{oHoB
Brrpyca
renarula
C.
B
Hacrof,Ir{ee
BpeMt
noArBepAu-fb
6uoxnN,rr,r.lecx14r\a
MerortoM
r[axr
uHrla6uponauux
NS5A
neAI4nacBVpoM
orcyrcrByer,
rrocKoJrbry
NS5A
ue
o6:raAaer
rpepnaeHrarueuofi
$yHxuraefi.
Jla6oparopurre
eHuq
r4ccreAoBaHH.s
Ha
rrpeAMeT
onpeAeneHHq
yciloBLrfr
pe3l.icTeHTHocrII u
[epeKpecTHoa
pe3rrcreHTHocrll
yKa3bIBaIor,
qro
JreAI4nacBI4p
Bo3Aefi
crnyer
Ha N S
5
A'
CoQoc6ynup
qBnf,ercfl
uHru6uroporu
PHK-sasacuN{ofi
ronl4Mepa3bl
Bnpyca
rellarl4ra
C NS5B,
seo6xoAl.rvr
oit
Atn
pennnKaurru
Br{pyca.
Co$oc6ynrap
rpeAcraBrqer
co6ofi
HyKneorI4AHoe
rrponeKapcrBo,
Koropoe
B
npouecce
BHyrpI4KnerorlHoro
uera6olu:tr,la
o6pa:oeunaer
Sapvarconor